Hospira's quality issues weigh on Q4 results, 2012 forecast

The good news for Hospira: Quarterly sales rose 2.2% to more than $1 billion. The not-so-good: The costs of fixing manufacturing problems pushed earnings into the red. The company's net loss amounted to $212.3 million, or $1.30 per diluted share, Reuters reports.

According to documents filed with the Securities and Exchange Commission, Hospira's ($HSP) efforts to fix quality issues at its Rocky Mount, NC, facility have resulted in drug shortages, reduced production volume and associated costs. The company took charges of $36.8 million for third-party oversight and consulting costs in 2011, plus the financial fallout from reduced production. The company also took inventory losses of $28.5 million at the Rocky Mount facility.

The FDA scrutiny has led to manufacturing "interruptions [that] have adversely impacted, and continue to adversely impact, Hospira's ability to manufacture and sell its products," the company said in its 10-K filing. Hospira is expecting the manufacturing overhaul to continue to affect earnings: Its forecast for 2012 includes charges of 50 cents to 62 cents per share to cover the cost of addressing product and quality-related matters, Reuters reports.

- see the SEC filing
- get more from Reuters

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.